The Korean journal of helicobacter and upper gastrointestinal research (대한상부위장관⦁헬리코박터학회지)

Korean College of Helicobacter and upper Gastrointestinal Reseaarch (대한상부위장관ㆍ헬리코박터학회)
권호 표지
DOI QR코드

DOI QR Code

Risk Factors of Gastrointestinal Bleeding in Patients Receiving New Oral Anticoagulants

New Oral Anticoagulants를 복용하는 환자들에서 위장관 출혈의 위험인자

  • Lee, Ju Yup (Department of Internal Medicine, Keimyung University School of Medicine)
  • 이주엽 (계명대학교 의과대학 내과학교실)
  • Received : 2018.02.22
  • Accepted : 2018.04.29
  • Published : 2018.12.31
⟨ Previous Next ⟩

Abstract

New oral anticoagulants (NOACs) are now widely used for the prevention and treatment of venous thrombosis, and for the prevention of stroke and systemic embolism in patients with atrial fibrillation. As compared with warfarin, NOACs have the advantage of rapid onset of action and less drug interaction. However, they carry a higher risk of gastrointestinal (GI) bleeding than warfarin. The risk of GI bleeding in patients using NOACs varies according to the type and dose of the drug. By contrast, apixaban and edoxaban are reported to carry similar risks as warfarin, and the risks with dabigatran and rivaroxaban are higher than that with warfarin. In patients using NOACs, old age, impaired renal function, impaired liver function, concurrent use of antiplatelet agents, and nonsteroidal anti-inflammatory drugs are considered major risk factors of GI bleeding, and gastroprotective agents such as histamine-2 receptor antagonist and proton pump inhibitor have preventive effects. To prevent GI bleeding associated with NOACs, the characteristics of each NOAC and the risk factors of bleeding should be recognized.

Keywords

References

  1. Weitz JI, Harenberg J. New developments in anticoagulants: past, present and future. Thromb Haemost 2017;117:1283-1288. https://doi.org/10.1160/TH16-10-0807
  2. Desai J, Kolb JM, Weitz JI, Aisenberg J. Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies. Thromb Haemost 2013;110:205-212. https://doi.org/10.1160/TH13-02-0150
  3. Wikimedia Commons [Internet]. San Francisco: Wikimedia Foundaion, 2015 Sep 14 [cited 2018 Mar 30]. Available from: https://commons.wikimedia.org/wiki/File:Emostasi.svg.
  4. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e44S-e88S. https://doi.org/10.1378/chest.11-2292
  5. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e24S-e43S. https://doi.org/10.1378/chest.11-2291
  6. Parekh PJ, Merrell J, Clary M, Brush JE, Johnson DA. New anticoagulants and antiplatelet agents: a primer for the clinical gastroenterologist. Am J Gastroenterol 2014;109:9-19. https://doi.org/10.1038/ajg.2013.228
  7. Cheung KS, Leung WK. Gastrointestinal bleeding in patients on novel oral anticoagulants: risk, prevention and management. World J Gastroenterol 2017;23:1954-1963. https://doi.org/10.3748/wjg.v23.i11.1954
  8. Oh S. New oral anticoagulants. J Korean Med Assoc 2013;56:57-61. https://doi.org/10.5124/jkma.2013.56.1.57
  9. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151. https://doi.org/10.1056/NEJMoa0905561
  10. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011;123:2363-2372. https://doi.org/10.1161/CIRCULATIONAHA.110.004747
  11. Larsen TB, Rasmussen LH, Skjoth F, et al. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013;61:2264-2273. https://doi.org/10.1016/j.jacc.2013.03.020
  12. Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol 2013;76:455-466. https://doi.org/10.1111/bcp.12075
  13. Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015;17:1467-1507. https://doi.org/10.1093/europace/euv309
  14. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891. https://doi.org/10.1056/NEJMoa1009638
  15. Goodman SG, Wojdyla DM, Piccini JP, et al. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol 2014;63:891-900. https://doi.org/10.1016/j.jacc.2013.11.013
  16. Abraham NS, Singh S, Alexander GC, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ 2015;350:h1857. https://doi.org/10.1136/bmj.h1857
  17. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-992. https://doi.org/10.1056/NEJMoa1107039
  18. Diener HC, Aisenberg J, Ansell J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. Eur Heart J 2017;38:860-868.
  19. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-2104. https://doi.org/10.1056/NEJMoa1310907
  20. Desai J, Granger CB, Weitz JI, Aisenberg J. Novel oral anticoagulants in gastroenterology practice. Gastrointest Endosc 2013;78:227-239. https://doi.org/10.1016/j.gie.2013.04.179
  21. Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625-651. https://doi.org/10.1093/europace/eut083
  22. Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011;50:675-686. https://doi.org/10.2165/11595320-000000000-00000
  23. Leil TA, Feng Y, Zhang L, Paccaly A, Mohan P, Pfister M. Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose. Clin Pharmacol Ther 2010;88:375-382. https://doi.org/10.1038/clpt.2010.106
  24. Graham DJ, Reichman ME, Wernecke M, et al. Stroke, bleeding, and mortality risks in elderly medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med 2016;176:1662-1671. https://doi.org/10.1001/jamainternmed.2016.5954
  25. Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation 2013;127:634-640. https://doi.org/10.1161/CIRCULATIONAHA.112.115386
  26. Jang SW. New oral anticoagulants: general features and review of pivotal clinical trials. Korean J Helicobacter Up Gastrointest Res 2016;16:178-184. https://doi.org/10.7704/kjhugr.2016.16.4.178
  27. Lau YC, Proietti M, Guiducci E, Blann AD, Lip GYH. Atrial fibrillation and thromboembolism in patients with chronic kidney disease. J Am Coll Cardiol 2016;68:1452-1464. https://doi.org/10.1016/j.jacc.2016.06.057
  28. Gong IY, Kim RB. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Can J Cardiol 2013;29(7 Suppl):S24-S33. https://doi.org/10.1016/j.cjca.2013.04.002
  29. Chan EW, Lau WC, Leung WK, et al. Prevention of dabigatran-related gastrointestinal bleeding with gastroprotective agents: a population-based study. Gastroenterology 2015;149:586-595.e3. https://doi.org/10.1053/j.gastro.2015.05.002
  30. Miller CS, Dorreen A, Martel M, Huynh T, Barkun AN. Risk of gastrointestinal bleeding in patients taking non-vitamin K antagonist oral anticoagulants: a systematic review and metaanalysis. Clin Gastroenterol Hepatol 2017;15:1674-1683.e3. https://doi.org/10.1016/j.cgh.2017.04.031
  31. Cangemi DJ, Krill T, Weideman R, Cipher DJ, Spechler SJ, Feagins LA. A Comparison of the rate of gastrointestinal bleeding in patients taking non-vitamin K antagonist oral anticoagulants or warfarin. Am J Gastroenterol 2017;112:734-739. https://doi.org/10.1038/ajg.2017.39